Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026)
Nuvalent's (NUVL) quarterly Amortizatization of Intangibles came in at $1.8 million in Q1 2026, down 57.27% YoY from $4.3 million in Q1 2025, and down 90.98% on a QoQ basis from $20.3 million in Q4 2025.
Analysis
Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Amortizatization of Intangibles data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 57.27% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (down 61.25% YoY) and the FY2025 annual result came in at $11.1 million, down 24.28% from the prior year.
- Amortizatization of Intangibles slipped to $1.8 million in Q1 2026, from $20.3 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $24.4 million in Q4 2024 to a low of -$11.3 million in Q2 2025.
- A 5-year average of $2.2 million and a median of -$833000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 2275.99% in 2023, down 87566.67% in 2023.
- Tracing NUVL's Amortizatization of Intangibles over 5 years: stood at -$833000.0 in 2022, then surged by 2275.99% to $18.1 million in 2023, then surged by 34.64% to $24.4 million in 2024, then retreated by 16.89% to $20.3 million in 2025, then plunged by 90.98% to $1.8 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.8 million (Q1 2026), $20.3 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 1.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -11.27 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 24.41 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.38 Mn |
| Dec 31, 2023 | 18.13 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Jun 30, 2023 | -2.85 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Dec 31, 2022 | -833,000.00 |
| Sep 30, 2022 | -3,000.00 |
| Jun 30, 2022 | 187,000.00 |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 214,000.00 |
| Sep 30, 2021 | 1,000.00 |